Separate sub-group analyses for patients above and below an HbA1c of 63.9 mmol/mol (8%), patients without history of CV and renal diseases, and patients using MET/SU produced similar risk estimates for CV events in the EBID and EBID + insulin groups. This evidence concerns the gene INS and kidney disorder.